Prior the immunotherapy era, potential options in the therapeutic armamentarium included kinase inhibitors targeting the PI3K/AKT/mTOR pathway that was known to be activated in bladder cancer [16, 34]. This evidence concerns the gene AKT1 and urinary bladder carcinoma.